Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 25 Oct 2016 Planned End Date changed from 1 Nov 2019 to 1 Oct 2019.
- 25 Oct 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Oct 2018.
- 25 Oct 2016 Status changed from not yet recruiting to recruiting.